Biocartis Group NV: Disclosure of a transparency notification
(Thomson Reuters ONE) -
PRESS RELEASE: REGULATED INFORMATION
Wednesday 13 July 2016, 07:00 CEST
Disclosure of a transparency notification
(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major
shareholdings)
Mechelen, Belgium, 13 July 2016 - Biocartis Group NV (the 'Company' or
'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels:
BCART), announces today in accordance with Article 14, paragraph 1 of the
Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers
whose shares are admitted to trading on a regulated market (the 'Belgian
Transparency Act'), that it received a transparency notification dated 11 July
2016 (the 'Notification'), indicating that the shareholding of Coöperatieve
AESCAP Venture I U.A. (which is controlled by AESCAP Venture Management B.V.)
has decreased below the 3% notification threshold.
The Notification contains the following information:
· Reason for the Notification: disposal of voting securities or voting
rights and downward crossing of the lowest threshold.
· Notification by: a parent undertaking or a controlling person.
· Persons subject to the notification requirement: Coöperatieve AESCAP
Venture I U.A., Barbara Strozzilaan 101, 1083HN, The Netherlands and AESCAP
Venture Management B.V., Barbara Strozzilaan 101, 1083HN, The Netherlands.
· Transaction date: 28 June 2016.
· Threshold that is crossed: 3%.
· Denominator: 40,589,188.
· Chain of controlled undertakings through which the holding was effectively
held:
AESCAP Venture Management B.V. controls Coöperatieve AESCAP Venture I U.A.
AESCAP Venture Management B.V. is not a controlled entity.
The Notification is available here on the website of the Company.
Pursuant to the Belgian Transparency Act and the articles of association of the
Company, a notification to the Company and the Belgian Financial Services and
Markets Authority ('FSMA') is required by all natural and legal persons in each
case where the percentage of voting rights in the Company held by such persons
reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every
subsequent multiple of 5%, of the total number of voting rights in the Company.
----- END ----
For more information:
Renate Degrave, Corporate Communications & Investor Relations
rdegrave(at)biocartis.com
+32 15 631 729
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at improving
clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-
result, real-time PCR (Polymerase Chain Reaction) system that offers accurate,
highly reliable molecular information from virtually any biological sample in
virtually any setting. Biocartis launched the Idylla(TM) platform in September
2014. Biocartis is developing and marketing a rapidly expanding test menu
addressing key unmet clinical needs in oncology and infectious diseases. These
areas represent respectively the fastest growing and largest segments of the MDx
market worldwide. Today, Biocartis has five oncology tests and two infectious
disease tests on the market. More information: www.biocartis.com. Press Photo
Library available here. Follow us on Twitter: (at)Biocartis_.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biocartis Group NV via GlobeNewswire
[HUG#2028108]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="First Majestic Produces 4.7 Million Silver Eqv. Ounces in Second QuarterDatum: 13.07.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 482992
Anzahl Zeichen: 4593
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biocartis Group NV: Disclosure of a transparency notification"
steht unter der journalistisch-redaktionellen Verantwortung von
Biocartis Group NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
